MedTrace Logo

Study of LW402 in Moderate-to-Severe Atopic Dermatitis

NCT07186387 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2025-10-02

No results posted yet for this study

Summary

This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

LW402

LW402 tablets

DRUG

LW402 placebo

LW402 placebo tablets

Sponsors & Collaborators

  • Shanghai Longwood Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-11
Primary Completion
2024-09-25
Completion
2025-02-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07186387 on ClinicalTrials.gov